Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 5,060 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Carisma Therapeutics Inc | CARM | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.07 | 4.29% | 1.70 | 07:02:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.63 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 90 | 5,060 | - | 1.53 - 9.7662 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:03:46 | formt | 200 | US$ 1.70 | USD |
Carisma Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 65.78M | 40.36M | - | 14.92M | -86.88M | -2.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Carisma Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CARM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.67 | 1.7099 | 1.60 | 1.64 | 94,760 | 0.03 | 1.80% |
| 1 Month | 1.98 | 2.0497 | 1.53 | 1.80 | 160,408 | -0.28 | -14.14% |
| 3 Months | 2.00 | 2.77 | 1.53 | 2.18 | 167,704 | -0.30 | -15.00% |
| 6 Months | 3.00 | 3.4179 | 1.53 | 2.42 | 169,432 | -1.30 | -43.33% |
| 1 Year | 4.10 | 9.7662 | 1.53 | 4.78 | 222,805 | -2.40 | -58.54% |
| 3 Years | 5.79 | 9.7662 | 1.53 | 4.65 | 216,524 | -4.09 | -70.64% |
| 5 Years | 5.79 | 9.7662 | 1.53 | 4.65 | 216,524 | -4.09 | -70.64% |
Carisma Therapeutics Description
| Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. |
